AS3MT promoter hypermethylation as an epigenetic biomarker for arsenic-induced skin lesions: a case–control study
- 23 July 2026
- journal article
- research article
- Published by Springer Nature in Environmental Geochemistry and Health
- Vol. 48 (11) , 480
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (41977400)
- Key R&D and Achievement Transformation Program of Inner Mongolia Autonomous Region (2025YFSH0139)
This publication has 65 references indexed in Scilit:
- AS3MT Gene Variant Shows Association with Skin Lesions in an Arsenic Exposed Population of IndiaBiological Trace Element Research, 2025
- Association between arsenic (+3 oxidation state) methyltransferase gene polymorphisms and arsenic methylation capacity in rural residents of northern China: a cross-sectional studyArchives of Toxicology, 2023
- Cutaneous Manifestations and Treatment of Arsenic Toxicity: A Systematic ReviewSkin Health and Disease, 2023
- Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directionsAmerican Journal of Hematology, 2022
- Mechanistic understanding of the toxic effects of arsenic and warfare arsenicals on human health and environmentCell Biology and Toxicology, 2022
- Groundwater Arsenic and Fluoride and Associated Arsenicosis and Fluorosis in China: Occurrence, Distribution and ManagementExposure and Health, 2020
- Individual susceptibility to arsenic-induced diseases: the role of host genetics, nutritional status, and the gut microbiomeMammalian Genome, 2018
- Genetic variation in arsenic (+3 oxidation state) methyltransferase (AS3MT), arsenic metabolism and risk of basal cell carcinoma in a European populationEnvironmental and Molecular Mutagenesis, 2014
- Differential methylation of the arsenic (III) methyltransferase promoter according to arsenic exposureArchives of Toxicology, 2013
- Monomethylarsonous Acid (MMAIII) Is More Toxic Than Arsenite in Chang Human HepatocytesToxicology and Applied Pharmacology, 2000